Welcome to our dedicated page for Palatin Technologies news (Ticker: $PTN), a resource for investors and traders seeking the latest updates and insights on Palatin Technologies stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Palatin Technologies's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Palatin Technologies's position in the market.
News
Rhea-AI Summary
Cosette Pharmaceuticals, Inc. (PTN) has completed the acquisition of Vyleesi®, the only FDA-approved as-needed treatment for the approximately 6 million premenopausal women who suffer from Hypoactive Sexual Desire Disorder (HSDD). The acquisition adds another commercial stage, patent-protected product to Cosette’s rapidly expanding women’s health portfolio. Vyleesi® has experienced 8 consecutive quarters of double-digit prescription growth and includes 5 Orange Book listed patents with protection up to 2041.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.62%
Tags
-
Rhea-AI Summary
Palatin Technologies, Inc. (NYSE American: PTN) sells Vyleesi® to Cosette Pharmaceuticals for $12 million upfront and up to $159 million in sales-based milestones
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.07%
Tags
-
News
Rhea-AI Summary
Palatin Technologies, Inc. (NYSE American: PTN) has received approval for its plan to come into compliance with NYSE American's continued listing standards. The company must regain compliance by April 10, 2025, and is exploring funding avenues to achieve this.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
Rhea-AI Summary
Palatin Technologies, Inc. (PTN): Enrollment complete in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease with 570 patients enrolled. Topline data expected late 4Q 2023. Phase 2 Clinical Study of Oral PL8177 in Patients with Ulcerative Colitis interim analysis targeted for 1Q 2024. Vyleesi® gross product revenue increased 11% over the prior quarter.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.48%
Tags
-
Rhea-AI Summary
Palatin Technologies, Inc. (NYSE American: PTN) will release its Q1 fiscal year 2024 operating results on November 14, 2023, followed by a conference call and live audio webcast. The call will provide an update on the company's development programs and a review of its operating results.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4%
Tags
-
Rhea-AI Summary
Palatin Technologies, Inc. has closed its registered direct offering, raising approximately $5 million in gross proceeds. The company sold 2,358,491 shares of common stock at a purchase price of $2.12 per share, and also issued warrants to purchase up to the same number of shares. The net proceeds will be used for general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.38%
Tags
Rhea-AI Summary
Palatin Technologies announces definitive agreement for issuance and sale of common stock and warrants
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.75%
Tags
-
News
Rhea-AI Summary
Palatin Technologies reports 7 consecutive quarters of double-digit growth in product revenue and prescriptions dispensed
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
22.54%
Tags
-
Rhea-AI Summary
Palatin Technologies plans to initiate a clinical study of its melanocortin 4 receptor (MC4R) agonist, bremelanotide, in combination with a Glucagon Like Peptide-1 (GLP-1) agonist for treating obesity. Preclinical data and prior clinical studies support the potential of Palatin's melanocortin agonists for weight loss. The combination therapy aims to improve treatment adherence and promote long-term weight loss.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.7%
Tags
Rhea-AI Summary
Palatin Technologies presents data on the impact of PL8177 in treating inflammatory diseases at UEG Week 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.16%
Tags
Palatin Technologies, Inc.
NYSE:PTN
PTN Rankings
PTN Stock Data
32.27M
15.54M
3.35%
10.72%
9.02%
Pharmaceutical Preparation Manufacturing
Manufacturing
United States of America
CRANBURY
About PTN
palatin technologies, inc., a specialized biopharmaceutical company, develops targeted receptor-specific therapeutics for the treatment of various diseases in the united states. the company's lead product is vyleesi, a melanocortin receptor agonist for the treatment of premenopausal women with acquired, generalized hypoactive sexual desire disorder. it is also developing oral pl8177, a selective melanocortin receptor (mcr) 1 agonist peptide that has completed phase i clinical trial for the treatment of inflammatory bowel diseases; and systemic pl8177, which has completed phase i clinical trial for treating non-infectious uveitis and covid-19. in addition, the company engages in the development of pl9643, a peptide melanocortin agonist active at multiple mcrs, including mc1r and mc5r for anti-inflammatory ocular indications, such as dry eye disease; and melanocortin peptides for diabetic retinopathy. further, it is developing pl3994, a natriuretic peptide receptor (npr)-a agonist and sy